Kuros Biosciences AG from Schlieren in the canton of Zurich has received approval from the US Food and Drug Administration (FDA) for the use of MagnetOs Flex Matrix in the interbody space. According to a statement, MagnetOs Flex Matrix can now be used in any interbody space such as the cervical spine, thoracic spine or lumbar spine, as well as in any cage that is approved for use with a bone graft substitute. A cage serves as a space holder in the spine to substitute a disc that no longer functions.
Interbody cages are used in nearly half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the US. MagnetOs Flex Matrix is particularly suitable for interbody applications as it remains stable and flexible even when wet due to its excellent granule retention. It can therefore be inserted either via a funnel or directly into a cage of any size.
“This is an important milestone for our company, as well as for the surgical community. With this clearance, we have a substantial commercial opportunity to re-engage with surgeons who were previously unable to use our MagnetOs Flex Matrix product on-label for interbody procedures,” commented Chris Fair, Kuros CEO, in the statement.
Kuros Biosciences AG is a spin-off from the University of Zurich (UZH) and the Federal Institute of Technology in Zurich (ETH). The company is headquartered in the Bio-Technopark Schlieren-Zürich. ce/gba